Identifying Genetic Targets in Gynecological Tumors

NCT07169396 · tracked via the Priya Life Science Italy tracker

Sponsor

Azienda USL Reggio Emilia - IRCCS

Phase

Observational

Started

2021-11-17

Last updated

2026-07-24

Condition(s) studied

Ovarian Cancer

Investigational drug(s) / intervention(s)

RNA extraction and gene expression

RNA extraction and gene expression: RNA extraction and gene expression

Study summary

This observational study aims to identfy genetic targets involved in the pathogenesis of gynecological tumors, with a focus on high-grade serous ovarian carcinoma. Using a triple approach - in silico, ex vivo and in vitro - the study will investigate the role of gonadotropins and their related signaling pathways in the epithelial ovarian cancers. Gene and protein expression levels will be evaluated through transcriptomic analysis, immunohistochemistry and functional assays on tumor cell lines. The goal is to uncover potential diagnostic or therapeutic targets in gynecological malignancies.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult women ≥18 years old * Histologically confirmed diagnosis of epithelial ovarian cancer (including high- grade serous, endometrioid, mucinous, clear cell, or mesonephric-like histotypes) * Signed informed consent (for prospective cases) or ethically approved waiver (for retrospective samples) Exclusion Criteria: * Refusal to sign informed consent * Diagnosis of low-grade or non-epithelial ovarian tumors * Patients whose clinical or pathological data are unavailable or insufficient for study inclusion

Primary outcome measure(s)

Gene expression profiling of selected target genes — 18 months
Quantification of gene expression levels (e.g., PRKAR1A, GNAS, GNAQ, ERBB2, GPM6B, etc.) in ovarian tumor tissue vs normal ovarian epithelium using digital PCR.

Trial sites (1)

Facility	City	Region	Status
Azienda USL IRCCS di Reggio Emilia	Reggio Emilia	Italy	Recruiting

More Azienda USL Reggio Emilia - IRCCS trials in Italy

Vocational Rehabilitation for the Return to Work of Breast Cancer Patients: a Feasibility Study Active, not recruiting

Tomosynthesis as Primary Test for Breast Cancer Screening Active, not recruiting

Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study Recruiting

Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD Recruiting

Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma Recruiting

Other trials for the same condition

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Recruiting

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Active, not recruiting

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07169396 on ClinicalTrials.gov ↗ ← All trials in Italy